[HTML][HTML] Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2: A phase 1 randomized clinical trial
…, O Schönborn‑Kellenberger, D Vahrenhorst… - Wiener Klinische …, 2021 - Springer
Background We used the RNActive® technology platform (CureVac NV, Tübingen, Germany)
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding …
Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers
…, G Quintini, O Schönborn-Kellenberger, D Vahrenhorst… - MedRxiv, 2020 - medrxiv.org
There is an urgent need for vaccines to counter the COVID-19 pandemic due to infections
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
with severe acute respiratory syndrome coronavirus (SARS-CoV-2). Evidence from …
[HTML][HTML] Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
…, P Mann, G Quintini, B Srivastava, D Vahrenhorst… - Vaccine: X, 2022 - Elsevier
Background The COVID-19 vaccine candidate CVnCoV comprises sequence-optimized
mRNA encoding SARS-CoV-2 S-protein encapsulated in lipid nanoparticles. In this phase 2a …
mRNA encoding SARS-CoV-2 S-protein encapsulated in lipid nanoparticles. In this phase 2a …
[HTML][HTML] Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity
OO Wolz, D Vahrenhorst, G Quintini, C Lemberg… - Vaccines, 2024 - mdpi.com
Vaccines are highly effective at preventing severe coronavirus disease (COVID-19). With
mRNA vaccines, further research is needed to understand the association between …
mRNA vaccines, further research is needed to understand the association between …
Corrigendum to “Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study”[Vaccine: X 11 (2022) …
…, P Mann, G Quintini, B Srivastava, D Vahrenhorst… - Vaccine: X, 2023 - ncbi.nlm.nih.gov
… Koch, d Sandra Lazzaro, d Philipp Mann, f Gianluca Quintini, d Barkha Srivastava, d Dominik
Vahrenhorst, d Philipp von Eisenhart-Rothe, d Olaf-Oliver Wolz, d and Lidia Oostvogels f …
Vahrenhorst, d Philipp von Eisenhart-Rothe, d Olaf-Oliver Wolz, d and Lidia Oostvogels f …
[HTML][HTML] 784 Immune profiling of patients with advanced melanoma intratumorally treated with CV8102 as a single-agent or in combination with anti-PD-1 antibodies …
…, T Eigentler, B Schmitt-Bormann, D Vahrenhorst… - 2022 - jitc.bmj.com
Background CV8102 is a non-coding, non-capped RNA complexed with a carrier peptide
activating the innate (via TLR7/8, RIG-I) and adaptive immune system. An ongoing expansion …
activating the innate (via TLR7/8, RIG-I) and adaptive immune system. An ongoing expansion …
[HTML][HTML] 473 Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD …
…, F Funkner, P Wengenmayer, D Vahrenhorst… - 2021 - jitc.bmj.com
Background CV8102 is a non-coding, non-capped RNA complexed with a carrier peptide
activating the innate (via TLR7/8, RIG-I) and adaptive immune system. An ongoing phase I trial …
activating the innate (via TLR7/8, RIG-I) and adaptive immune system. An ongoing phase I trial …
On-and off target toxicity profiling for adoptive cell therapy by mass spectrometry-based immunopeptidome analysis of primary human normal tissues
…, L Stevermann, A Sonntag, F Hoffgaard, D Vahrenhorst… - Cancer Research, 2016 - AACR
A major constraint for the broad and safe application of Adoptive Cellular Therapy (ACT) is
the limited number of validated tumor targets, especially for solid tumors. For T-cell receptor (…
the limited number of validated tumor targets, especially for solid tumors. For T-cell receptor (…
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded …
PG Kremsner, RAA Guerrero, E Arana-Arri… - The Lancet Infectious …, 2022 - thelancet.com
Background Additional safe and efficacious vaccines are needed to control the COVID-19
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA …
[HTML][HTML] A third dose of the COVID-19 vaccine, CVnCoV, increased the neutralizing activity against the SARS-CoV-2 wild-type and delta variant
OO Wolz, SK Kays, H Junker, SD Koch, P Mann… - Vaccines, 2022 - mdpi.com
A third dose of CVnCoV, a former candidate mRNA vaccine against SARS-CoV-2, was
previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in …
previously shown to boost neutralizing antibody responses against SARS-CoV-2 wild-type in …